Vorinostat
From Wikipedia, the free encyclopedia
 |
|
|
Vorinostat
|
|
| Systematic (IUPAC) name | |
| N-hydroxy-N'-phenyl-octanediamide | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C14H20N2O3 |
| Mol. mass | 264.32 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 71% |
| Metabolism | Hepatic glucuronidation and oxidation CYP system not involved |
| Half life | 2 hours |
| Excretion | Renal (negligible) |
| Therapeutic considerations | |
| Licence data |
|
| Pregnancy cat. |
D(US) |
| Legal status | |
| Routes | Oral |
Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA) is a member of a larger class of compounds that inhibit histone deacetylases (HDAC). Histone deacetylase inhibitors (HDI) have a broad spectrum of epigenetic activities. SAHA is marketed under the name Vorinostat, brand name Zolinza, for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It has been used to treat Sézary's disease.[1]
A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier studies). Further brain tumor trials are planned in which vorinostat will be combined with other drugs.
Zolinza was approved by the U.S. Food and Drug Administration (FDA) for the treatment of CTCL on October 6, 2006, and it is manufactured by Patheon, Inc., in Mississauga, Ontario, Canada, for Merck & Co., Inc., White House Station, New Jersey.
[edit] References
- ^ Cuneo A, Castoldi. Mycosis fungoidses/Sezary's syndrome. Retrieved on 2008-02-15.
- Merck & Co. (June 7, 2006). "ZOLINZA, Merck's Investigational Medicine for Advanced Cutaneous T-Cell Lymphoma (CTCL), To Receive Priority Review from U.S. Food and Drug Administration". Press release. Retrieved on 2006-10-06.
- Food and Drug Administration (October 6, 2006). "FDA Approves New Drug for Skin Cancer, Zolinza". Press release. Retrieved on 2006-10-06.
- Mayo Clinic (June 3, 2007). "Vorinostat shows anti-cancer activity in recurrent gliomas". Press release. Retrieved on 2007-06-03.
|
||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
